Department of Internal Medicine, National Taiwan University Hospital, Yun-Lin Branch, Yun-Lin, Taiwan.
Department of Internal Medicine, National Taiwan University Hospital, 7 Chung-Shan South Road, Taipei 10002, Taiwan.
PPAR Res. 2014;2014:917823. doi: 10.1155/2014/917823. Epub 2014 May 22.
Silencing of acid-labile subunit (ALS) improved glucose metabolism in animal models. The aim of this study is to evaluate the effects of rosiglitazone (RSG) on ALS levels in individuals with type 2 diabetes. A randomized, double-blind, placebo-controlled trial was conducted. Subjects with type 2 diabetes mellitus were randomly distributed to an RSG-treated (n = 30) or a placebo (n = 31) group. Patients were evaluated prior to treatment at baseline and at 12 and 24 weeks after treatment. At baseline, ALS levels were negatively associated with low-density lipoprotein cholesterol (LDLc) levels and homeostatic model assessment version 2 insulin sensitivity (HOMA2-%S). Over 24 weeks, there was a significantly greater reduction in ALS levels in the nonobese RSG-treated individuals than placebo-treated group. The effect of RSG on ALS was not significant in obese individuals. Fasting plasma glucose and hemoglobin A1c were reduced, but total cholesterol and LDLc were increased, in patients on RSG. Change in ALS levels predicted changes in total cholesterol and HOMA2-%S over time. This study suggested a BMI-dependent effect of RSG treatment on ALS levels. Reduction of ALS by RSG increases the risk of atherosclerosis in individuals with type 2 diabetes.
酸不稳定亚基（ALS）的沉默改善了动物模型中的葡萄糖代谢。本研究旨在评估罗格列酮（RSG）对 2 型糖尿病个体中 ALS 水平的影响。进行了一项随机、双盲、安慰剂对照试验。2 型糖尿病患者被随机分为 RSG 治疗组（n=30）和安慰剂组（n=31）。患者在治疗前、治疗后 12 周和 24 周进行评估。在基线时，ALS 水平与低密度脂蛋白胆固醇（LDLc）水平和稳态模型评估 2 胰岛素敏感性（HOMA2-%S）呈负相关。在 24 周内，非肥胖的 RSG 治疗个体的 ALS 水平降低幅度明显大于安慰剂治疗组。肥胖个体中，RSG 对 ALS 的影响不显著。RSG 治疗可降低空腹血糖和糖化血红蛋白，但总胆固醇和 LDLc 升高。ALS 水平的变化可预测总胆固醇和 HOMA2-%S 随时间的变化。本研究表明，RSG 治疗对 ALS 水平的影响存在 BMI 依赖性。RSG 降低 ALS 会增加 2 型糖尿病患者发生动脉粥样硬化的风险。
